Control Bionics Ltd (CBL) - Net Assets
Based on the latest financial reports, Control Bionics Ltd (CBL) has net assets worth AU$7.73 Million AUD (≈ $5.47 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.93 Million ≈ $7.03 Million USD) and total liabilities (AU$2.20 Million ≈ $1.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Control Bionics Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$7.73 Million |
| % of Total Assets | 77.81% |
| Annual Growth Rate | -28.55% |
| 5-Year Change | -67.9% |
| 10-Year Change | -97.16% |
| Growth Volatility | 101.41 |
Control Bionics Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Control Bionics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Control Bionics Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Control Bionics Ltd (2014–2024)
The table below shows the annual net assets of Control Bionics Ltd from 2014 to 2024. For live valuation and market cap data, see Control Bionics Ltd (CBL) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
-12.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
-11.92% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
-40.32% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
-30.53% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
-14.72% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
+298.26% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
-17.02% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
-97.92% |
| 2016-12-31 | AU$292.62 Million ≈ $207.05 Million |
+51.08% |
| 2015-12-31 | AU$193.69 Million ≈ $137.05 Million |
+21.89% |
| 2014-12-31 | AU$158.90 Million ≈ $112.43 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Control Bionics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 174.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$40.37 Million | 732.76% |
| Other Comprehensive Income | AU$530.78K | 9.64% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$5.51 Million | 100.00% |
Control Bionics Ltd Competitors by Market Cap
The table below lists competitors of Control Bionics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aelis Farma SA
PA:AELIS
|
$18.95 Million |
|
Daesung Microbiological Labs. Co. Ltd
KQ:036480
|
$18.95 Million |
|
Keller Group PLC
LSE:KLR
|
$18.96 Million |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
$18.96 Million |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
$18.95 Million |
|
Vincit Group Oyj
HE:VINCIT
|
$18.93 Million |
|
BIT Mining Limited
NYSE:BTCM
|
$18.91 Million |
|
Salee Colour Public Company Limited
BK:COLOR
|
$18.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Control Bionics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,267,708 to 5,508,725, a change of -758,983 (-12.1%).
- Net loss of 6,108,667 reduced equity.
- Share repurchases of 5,406,220 reduced equity.
- Other comprehensive income increased equity by 136,430.
- Other factors increased equity by 10,619,474.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-6.11 Million | -110.89% |
| Share Repurchases | AU$5.41 Million | -98.14% |
| Other Comprehensive Income | AU$136.43K | +2.48% |
| Other Changes | AU$10.62 Million | +192.78% |
| Total Change | AU$- | -12.11% |
Book Value vs Market Value Analysis
This analysis compares Control Bionics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.09x to 3.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | AU$0.72 | AU$0.07 | x |
| 2015-12-31 | AU$1.14 | AU$0.07 | x |
| 2016-12-31 | AU$1.31 | AU$0.07 | x |
| 2017-12-31 | AU$0.07 | AU$0.07 | x |
| 2018-12-31 | AU$0.05 | AU$0.07 | x |
| 2019-12-31 | AU$0.22 | AU$0.07 | x |
| 2020-12-31 | AU$0.19 | AU$0.07 | x |
| 2021-12-31 | AU$0.13 | AU$0.07 | x |
| 2022-12-31 | AU$0.07 | AU$0.07 | x |
| 2023-12-31 | AU$0.04 | AU$0.07 | x |
| 2024-12-31 | AU$0.02 | AU$0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Control Bionics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -110.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.41%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.49x
- Recent ROE (-110.89%) is below the historical average (-38.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 18.32% | 14.29% | 0.33x | 3.84x | AU$16.12 Million |
| 2016 | 10.16% | 9.19% | 0.27x | 4.11x | AU$481.00K |
| 2017 | -15.97% | -120.74% | 0.13x | 1.04x | AU$-1.58 Million |
| 2018 | -38.22% | -247.19% | 0.14x | 1.07x | AU$-2.44 Million |
| 2019 | -5.00% | -32.44% | 0.15x | 1.02x | AU$-3.02 Million |
| 2020 | -20.69% | -86.85% | 0.22x | 1.07x | AU$-5.27 Million |
| 2021 | -51.24% | -135.72% | 0.34x | 1.13x | AU$-7.30 Million |
| 2022 | -78.78% | -99.80% | 0.65x | 1.22x | AU$-6.35 Million |
| 2023 | -94.35% | -110.52% | 0.59x | 1.44x | AU$-6.54 Million |
| 2024 | -110.89% | -99.41% | 0.75x | 1.49x | AU$-6.66 Million |
Industry Comparison
This section compares Control Bionics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $67,261,649
- Average return on equity (ROE) among peers: -33.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Control Bionics Ltd (CBL) | AU$7.73 Million | 18.32% | 0.29x | $18.95 Million |
| 4DMEDICAL Ltd (4DX) | $64.24 Million | -46.81% | 0.48x | $1.63 Billion |
| Adherium Ltd (ADR) | $-4.76 Million | 0.00% | 0.00x | $7.37 Million |
| Aroa Biosurgery Ltd (ARX) | $6.92 Million | -23.35% | 0.08x | $150.91 Million |
| Atomo Diagnostics Ltd (AT1) | $-5.47 Million | 0.00% | 0.00x | $13.76 Million |
| Avita Medical Inc (AVH) | $5.12 Million | -224.74% | 0.50x | $132.15 Million |
| Anteris Technologies Global Corp (AVR) | $22.64 Million | -106.07% | 0.18x | $570.83 Million |
| Cardiex Ltd (CDX) | $4.88 Million | 56.04% | 0.31x | $13.23 Million |
| Compumedics Ltd (CMP) | $8.51 Million | 8.89% | 1.37x | $41.70 Million |
| Cochlear Ltd (COH) | $503.28 Million | 35.79% | 0.47x | $4.60 Billion |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more